MaaT Pharma SA (ENXTPA: MAAT)
Health Care · Biotechnology · FR
€3.05
-4.39% today · -40.7% 1Y
MaaT Pharma SA (ENXTPA: MAAT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $70.17M and employs 56 people.
Over the last twelve months the share price has lost 40.7%, trading between 2.32 and 8.62.
Tweenvest scores MaaT Pharma SA across four factors: quality 23/100, value 48/100. Its strongest factor is value.
MAAT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $70.17M
- Revenue (TTM)
- $5.31M
- P/E
- —
- EPS
- -1.95
- Dividend yield
- —
- Beta (5Y)
- 0.40
- 52-week high
- €8.62
- 52-week low
- €2.32
- Avg volume (3M)
- —
- Shares outstanding
- 18.84M
- Employees
- 56
- Next earnings
- —
About MaaT Pharma SA
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
- ISIN
- FR0012634822
- Founded
- 2014
- Listed since
- Nov 8, 2021
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.94 | -0.01% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $442.44 | +0.71% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.71 | +0.40% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $550.47 | +0.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $829.53 | -0.54% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.45 | -3.87% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.